The Parkinson's Foundation announced on Monday that it has awarded community grants, valued at more than USD1.5m, for Parkinson's programmes in 38 states across the country.
For 2019, the Foundation's grant will focus on three areas including: programmes that provide a service for underserved PD communities, initiatives that reach the newly diagnosed and clinical trial education and participation that reach those under-represented in the PD community.
The USD1.5m in community grants range from a minimum of USD5,000 to a maximum of USD25,000 per grant application.
Through the community grants, the Foundation will support local health, wellness and educational programmes that address unmet needs in the Parkinson's disease (PD) community. The programmes include wellness, dance, music therapy and educational programmes that can help people with Parkinson's live better with the disease.
Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the US. It is associated with a progressive loss of motor control such as shaking or tremor at rest and lack of facial expression, as well as non-motor symptoms like depression and anxiety. The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure.
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD